TNF and rheumatoid arthritis: Previous studies have suggested there is no difference in the occurrence of nonvertebral osteoporotic fractures in patients with rheumatoid arthritis treated with the biologic or targeted DMARDs adalimumab, abatacept, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab, or tofacitinib [28] or with abatacept or tocilizumab compared to anti-TNF therapy [29].